BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34649021)

  • 1. Hematopoietic Cell Transplantation is Feasible in Patients with Prior COVID-19 Infection.
    Shah N; Dahi PB; Ponce DM; Sauter CS; Shaffer BC; Chung DJ; Politikos I; Lin RJ; Giralt SA; Papanicolaou G; Ramanathan LV; Perales MA; Kamboj M; Shah GL; Gyurkocza B
    Transplant Cell Ther; 2022 Jan; 28(1):55.e1-55.e5. PubMed ID: 34649021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
    Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
    Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19.
    Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI
    Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study.
    Hill JA; Martens MJ; Young JH; Bhavsar K; Kou J; Chen M; Lee LW; Baluch A; Dhodapkar MV; Nakamura R; Peyton K; Shahid Z; Armistead P; Westervelt P; McCarty J; McGuirk J; Hamadani M; DeWolf S; Hosszu K; Sharon E; Spahn A; Toor AA; Waldvogel S; Greenberger LM; Auletta JJ; Horowitz MM; Riches ML; Perales MA
    EClinicalMedicine; 2023 May; 59():101983. PubMed ID: 37128256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical presentation and outcomes of COVID-19 following hematopoietic cell transplantation and cellular therapy.
    Camargo JF; Mendoza MA; Lin R; Moroz IV; Anderson AD; Morris MI; Natori Y; Natori A; Raja M; Lekakis L; Beitinjaneh A; Jimenez A; Goodman M; Wang T; Komanduri KV; Pereira D
    Transpl Infect Dis; 2021 Aug; 23(4):e13625. PubMed ID: 33896088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for a severe disease course in children with SARS-COV-2 infection following hematopoietic cell transplantation in the pre-Omicron period: a prospective multinational Infectious Disease Working Party from the European Society for Blood and Marrow Transplantation group (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH) study.
    Averbuch D; de la Camara R; Tridello G; Knelange NS; Bykova TA; Ifversen M; Dobsinska V; Ayas M; Hamidieh AA; Pichler H; Perez-Martinez A; Cesaro S; Sundin M; Badell I; Bader P; Johansson JE; Mirci-Danicar O; Sedlacek P; Paillard C; Gibson B; Lawson S; Kroeger N; Corbacioglu S; Mikulska M; Piñana JL; Styczynski J; Ljungman P
    Bone Marrow Transplant; 2023 May; 58(5):558-566. PubMed ID: 36849806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case Report: Favorable outcome of allogeneic hematopoietic stem cell transplantation in SARSCoV2 positive recipient, risk-benefit balance between infection and leukemia.
    Oltolini C; Acerbis A; Orofino G; Racca S; Noviello M; Dispinseri S; Clementi N; Piemontese S; Xue E; Giglio F; Lupo Stanghellini MT; Diral E; Bruno A; Tassi E; Beretta V; Marzinotto I; Scarlatti G; Lampasona V; Ardemagni A; Sampaolo M; Bonini C; Corti C; Peccatori J; Castagna A; Ciceri F; Greco R
    Front Immunol; 2023; 14():1184956. PubMed ID: 37287986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy.
    Infante MS; Nemirovsky D; Devlin S; DeWolf S; Tamari R; Dahi PB; Lee YJ; Chung DJ; Politikos I; Barker J; Giralt SA; Babady NE; Ramanathan L; Papanicolaou GA; Seo S; Kamboj M; Perales MA; Shah GL
    Transplant Cell Ther; 2024 Jan; 30(1):116.e1-116.e12. PubMed ID: 37806446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation.
    Huang A; Cicin-Sain C; Pasin C; Epp S; Audigé A; Müller NJ; Nilsson J; Bankova A; Wolfensberger N; Vilinovszki O; Nair G; Hockl P; Schanz U; Kouyos RD; Hasse B; Zinkernagel AS; Trkola A; Manz MG; Abela IA; Müller AMS
    Transplant Cell Ther; 2022 Apr; 28(4):214.e1-214.e11. PubMed ID: 35092892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101).
    Hill JA; Martens MJ; Young JH; Bhavsar K; Kou J; Chen M; Lee LW; Baluch A; Dhodapkar MV; Nakamura R; Peyton K; Howard DS; Ibrahim U; Shahid Z; Armistead P; Westervelt P; McCarty J; McGuirk J; Hamadani M; DeWolf S; Hosszu K; Sharon E; Spahn A; Toor AA; Waldvogel S; Greenberger LM; Auletta JJ; Horowitz MM; Riches ML; Perales MA
    medRxiv; 2024 Jan; ():. PubMed ID: 38343800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation.
    Hütter-Krönke ML; Neagoie A; Blau IW; Wais V; Vuong L; Gantner A; Ahn J; Penack O; Schnell J; Nogai KA; Eberspächer B; Saadati M; Benner A; Bullinger L; Döhner H; Bunjes D; Sala E
    Front Immunol; 2023; 14():1174289. PubMed ID: 37207199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts.
    Jacob RP; Flynn J; Devlin SM; Maloy M; Giralt SA; Maslak P; O'Reilly RJ; Tonon JA; Perales MA; Avecilla ST; Cho C
    Transplant Cell Ther; 2021 Aug; 27(8):697.e1-697.e5. PubMed ID: 33991721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged SARS-CoV-2 infection during autologous hematopoietic stem cell transplantation from Hodgkin's lymphoma: a case report.
    Abakarim O; Lahlimi FE; Maghnouj O; Tazi I
    Pan Afr Med J; 2023; 44():133. PubMed ID: 37333782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation.
    El-Jawahri A; Chen YB; Brazauskas R; He N; Lee SJ; Knight JM; Majhail N; Buchbinder D; Schears RM; Wirk BM; Wood WA; Ahmed I; Aljurf M; Szer J; Beattie SM; Battiwalla M; Dandoy C; Diaz MA; D'Souza A; Freytes CO; Gajewski J; Gergis U; Hashmi SK; Jakubowski A; Kamble RT; Kindwall-Keller T; Lazarus HM; Malone AK; Marks DI; Meehan K; Savani BN; Olsson RF; Rizzieri D; Steinberg A; Speckhart D; Szwajcer D; Schoemans H; Seo S; Ustun C; Atsuta Y; Dalal J; Sales-Bonfim C; Khera N; Hahn T; Saber W
    Cancer; 2017 May; 123(10):1828-1838. PubMed ID: 28102896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group.
    Piñana JL; López-Corral L; Martino R; Montoro J; Vazquez L; Pérez A; Martin-Martin G; Facal-Malvar A; Ferrer E; Pascual MJ; Sanz-Linares G; Gago B; Sanchez-Salinas A; Villalon L; Conesa-Garcia V; Olave MT; López-Jimenez J; Marcos-Corrales S; García-Blázquez M; Garcia-Gutiérrez V; Hernández-Rivas JÁ; Saus A; Espigado I; Alonso C; Hernani R; Solano C; Ferrer-Lores B; Guerreiro M; Ruiz-García M; Muñoz-Bellido JL; Navarro D; Cedillo A; Sureda A;
    Am J Hematol; 2022 Jan; 97(1):30-42. PubMed ID: 34695229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody response to mRNA SARS-CoV-2 vaccination in 182 patients after allogeneic hematopoietic cell transplantation.
    Beerlage A; Leuzinger K; Valore L; Mathew R; Junker T; Drexler B; Passweg JR; Hirsch HH; Halter J
    Transpl Infect Dis; 2022 Jun; 24(3):e13828. PubMed ID: 35324045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons learned from COVID-19 pandemic: outcomes after SARS-CoV-2 infection in hematopoietic cell transplant and cell therapy recipients.
    Al-Ramahi JS; Shahzad M; Li K; DeJarnette S; Chaudhary SG; Lutfi F; Ahmed N; Balusu R; Bansal R; Abdelhakim H; Shune L; Singh AK; Abhyankar SH; McGuirk JP; Mushtaq MU
    Leuk Lymphoma; 2023 Dec; 64(12):1981-1991. PubMed ID: 37574842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity.
    Pourhassan H; La Rosa C; Chiuppesi F; Puing A; Aldoss I; Park Y; Zhou Q; Karpinski V; Faircloth K; Kaltcheva T; Johnson D; Francisco SO; Zaia JA; Nakamura R; Al Malki MM; Diamond DJ; Dadwal SS; Forman SJ
    Blood Adv; 2022 Mar; 6(6):1645-1650. PubMed ID: 35008104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.